knowledge -WSS

knowledge

author：comprehensive 2025-10-01 00:52:36 - browse：34436

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Bird flu reported in person exposed to presumably infected cattle

WSS

People with mental disorders often marry others with same

FDA has safety concerns on CRISPR

Pancreatic cancer is often deadly, but new discoveries are raising hope

Scientific mystery highlights the blind spots in genomics databases

Bird flu in dairy cattle: New measures to control spread to humans

Scientific mystery highlights the blind spots in genomics databases

explore

knowledge

leisure time

Walensky prepares to leave CDC — and Congress — behind

Young boy dies in trial for Pfizer Duchenne gene therapy

United colonoscopy coverage change 'may cost lives,' doctors say

Overprescribed: High cost isn't America's only drug problem

Guidelines to prevent youth baseball injuries need more muscle

Multiple sclerosis has subtypes with different best treatments: study

In Memoriam: Notable people who died in 2023

Gut bacteria may contribute to kidney autoimmunity, study finds

The high cost of giving birth even with insurance

Readout Newsletter: New research from Sanofi, Regeneron, etc.

knowledge

Testing for cancer recurrence creates a new limbo for patients

Diversifying clinical trials isn't enough to close racial gaps: study

Bird flu reported in person exposed to presumably infected cattle

Why Sanofi got shellacked over its spinoff

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

knowledge

knowledge

hotspot

focus